bioRxivMicrobiologyPreprint
Aglycone polyether ionophores as broad-spectrum agents inhibit multiple enveloped viruses including SARS-CoV-2 in vitro and successfully cure JEV infected mice
T. Liu, J.-Q. Li, M. Huang, Y.-N. Zhang, R. Liu, Z.-R. Zhang, Q.-Y. Zhang, Y. Wang, J. Liu, Z. Deng, B. Zhang, H.-Q. Ye
Abstract
Infections with zoonotic viruses, such as flaviviruses, influenza virus, and the SARS-CoV-2 pandemic coronavirus constitute an increasing global risk. Hence, an urgent need exists for the development of broad-spectrum antivirals to prevent such outbreaks. Here, we show that the maduramycin and CP-80,219 aglycone polyether ionophores exhibit effective broad-spectrum antiviral activity, against various viruses, including Japanese encephalitis virus (JEV), Dengue virus (DENV), Zika virus (ZIKV), and Chikungunya virus (CHIKV), while also exhibiting promising activity against PR8 influenza virus and SARS-CoV-2. Moreover, liposome-encapsulated maduramycin and CP-80,219 provide full protection for mice from infection with JEV in vivo. Mechanistic studies suggest that aglycone polyether ionophores primarily inhibit the viral replication step without blocking endosome acidification to promote the fusion between viral and cellular membranes. The successful application of liposomes containing aglycone polyether ionophores in JEV-infected mice offers hope to the development of broad-spectrum antiviral drugs like penicillin back to 1940s.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Ionophore antibiotic X-206 is a potent and selective inhibitor of SARS-CoV-2 infection in vitro
E. B. Svenningsen, J. T. Jensen, … T. B. Poulsen·bioRxiv·Jun 14, 2020
- Antiviral Sulfonated Polymersomes Inhibit Corona-, Influenza-, and Alphavirus
Sinead McCabe, Ruiqi Zhu, … Adrian Najer·bioRxiv·Oct 11, 2026
- Broad-spectrum antiviral activity of naproxen: from Influenza A to SARS-CoV-2 Coronavirus
O. Terrier, S. Dilly, … A. Slama-Schwok·bioRxiv·Apr 30, 2020
- Post-infection treatment with the E protein inhibitor BIT225 reduces disease severity and increases survival of k18-hACE2 transgenic mice infected with a lethal dose of SARS-CoV-2
Gary D. Ewart, Michael D. Bobardt, … Philippe A. Gallay·PLoS PathogensPeer-reviewed·Aug 7, 2023
- Antiviral activity of influenza A virus defective interfering particles against SARS-CoV-2 replication in vitro through stimulation of innate immunity
U. Rand, S. Y. Kupke, … D. Bruder·bioRxiv·Feb 19, 2021
- A natural broad-spectrum inhibitor of enveloped virus entry, effective against SARS-CoV-2 and Influenza A Virus in preclinical animal models.
R. Narayan, M. Sharma, … S. Tripathi·bioRxiv·Feb 16, 2022